<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01412736</url>
  </required_header>
  <id_info>
    <org_study_id>4563-003</org_study_id>
    <nct_id>NCT01412736</nct_id>
  </id_info>
  <brief_title>A Phase IIa Study of KHK4563</brief_title>
  <acronym>4563-003</acronym>
  <official_title>A Phase IIa , Double-blind, Placebo-controlled Dose-ranging Study to Evaluate the Efficacy and Safety of KHK4563 in Adults With Uncontrolled, Suspected Eosinophilic Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyowa Hakko Kirin Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kyowa Hakko Kirin Co., Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a double-blind, placebo-controlled dose-ranging study of KHK4563 to evaluate the
      effect of multiple-dose subcutaneous administration of KHK4563 on the annual asthma
      exacerbation rate in adult subjects with uncontrolled, suspected eosinophilic asthma.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>evaluation of the effect of multiple-dose subcutaneous(SC) administration of benralizumab on the annual asthma exacerbation rate in adult subjects with uncontrolled, suspected eosinophilic asthma.</measure>
    <time_frame>Immediately following the first administration of study drug through Study Week 52.</time_frame>
    <description>annual asthma exacerbation rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pulmonary function as assessed by Forced Expiratory Volume in 1 Second (FEV1) and Peak Expiratory flow (PEF)</measure>
    <time_frame>From first administration of study drug through Study Week 52.</time_frame>
    <description>Pre-dose/pre-bronchodilator Forced Expiratory Volume in 1 Second ( FEV1 ) at the study centre, morning and evening peak expiratory flow (PEF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Asthma control as assessed by ASTHMA CONTROL QUESTIONNAIRE6(ACQ6)</measure>
    <time_frame>From first administration of study drug through Study Week 52.</time_frame>
    <description>ASTHMA CONTROL QUESTIONNAIRE6(ACQ6)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>From first administration of study drug through Study Week 68.</time_frame>
    <description>Adverse Events/Serious Adverse Events (AE/SAE) - Laboratory variables - ECG (Electrocardiogram) - Physical Examination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time Profiles of Serum Concentration</measure>
    <time_frame>From first administration of study drug through Study Week 68</time_frame>
    <description>Serum benralizumab concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity by serum incidence rate of positive anti-drug antibody</measure>
    <time_frame>From first administration of study drug through Study Week 68</time_frame>
    <description>Anti-drug antibodies (ADA)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">106</enrollment>
  <condition>Uncontrolled and Suspected Eosinophilic Asthma</condition>
  <arm_group>
    <arm_group_label>2mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>sterile lyophilized formulation, 2mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>20mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>sterile lyophilized formulation, 20mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>100mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>sterile lyophilized formulation, 100mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>two SC administration on day 1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KHK4563</intervention_name>
    <description>every 4 weeks for the first 3 doses on Weeks 0 (Day 1), 4, and 8 and then every 8 weeks thereafter for the last 4 doses on Weeks 16, 24, 32, and 40.</description>
    <arm_group_label>2mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KHK4563</intervention_name>
    <description>every 4 weeks for the first 3 doses on Weeks 0 (Day 1), 4, and 8 and then every 8 weeks thereafter for the last 4 doses on Weeks 16, 24, 32, and 40.</description>
    <arm_group_label>20mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KHK4563</intervention_name>
    <description>every 4 weeks for the first 3 doses on Weeks 0 (Day 1), 4, and 8 and then every 8 weeks thereafter for the last 4 doses on Weeks 16, 24, 32, and 40.</description>
    <arm_group_label>100mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>every 4 weeks for the first 3 doses on Weeks 0 (Day 1), 4, and 8 and then every 8 weeks thereafter for the last 4 doses on Weeks 16, 24, 32, and 40.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 20 through 75 years at the time of Week −3 visit.

          2. Written informed consent obtained from the subject prior to performing any
             protocol-related procedures, including screening evaluations.

          3. Physician prescribed daily use of medium-dose or high-dose ICS plus LABA or any
             combination of sequential dosing of either medium-dose or high-dose ICS/LABA for at
             least 12 months prior to Week −3 visit. Dose must be stable for at least 30 days prior
             to Week −3 visit.

          4. At least 2, but not more than 6, documented asthma exacerbations in the 12 months
             prior to Week −3 visit that required use of a systemic corticosteroid burst.

        Exclusion Criteria

          1. Any condition (eg, any eosinophilic lower respiratory disease other than asthma,
             Churg-Strauss syndrome, hypereosinophilic syndrome, eosinophilic bronchitis,
             eosinophilic pneumonia, chronic obstructive pulmonary disease (COPD), bronchiectasis
             or cystic fibrosis (CF)) that, in the opinion of the investigator or Medical Expert,
             would interfere with evaluation of the investigational product or interpretation of
             subject safety or study results.

          2. Any clinically relevant abnormal findings in physical examination, vital signs,
             hematology, clinical chemistry, or urinalysis during screening period, which in the
             opinion of the investigator, may put the subject at risk because of his/her
             participation in the study, or may influence the results of the study, or the
             subject's ability to participate in the study.

          3. Acute upper or lower respiratory infections requiring antibiotics or antiviral
             medications within 30 days prior to Week −3 visit or during the screening period.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Nagoya-shi</city>
        <state>Aichi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toyota-shi</city>
        <state>Aichi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kamogawa-shi</city>
        <state>Chiba</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fukuoka-shi</city>
        <state>Fukuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ogaki-shi</city>
        <state>Gifu</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hiroshima-shi</city>
        <state>Hiroshima</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sapporo-shi</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Himeji-shi</city>
        <state>Hyogo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kobe-shi</city>
        <state>Hyogo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sagamihara-shi</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yokohama-shi</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kumamoto-shi</city>
        <state>Kumamoto</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kyoto-shi</city>
        <state>Kyoto</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nagasaki-shi</city>
        <state>Nagasaki</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kishiwada-shi</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Koshigaya-shi</city>
        <state>Saitama</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shizuoka-shi</city>
        <state>Shizuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Itabashi-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shinagawa-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shinjuku-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mizunami-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Osakasayama-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oura-gun</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seto-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chungcheongbuk-do</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gwangju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gyenggi-do</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Suwon-si</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 7, 2011</study_first_submitted>
  <study_first_submitted_qc>August 8, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 9, 2011</study_first_posted>
  <last_update_submitted>December 21, 2014</last_update_submitted>
  <last_update_submitted_qc>December 21, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 23, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
    <mesh_term>Pulmonary Eosinophilia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

